Hamza Hashmi is a Hematology physician. OpenAlex indexes 296 publications with 2,809 citations (h-index 26).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
171 Ashley Ave
Charleston, SC 294254692
Telephone
843-792-1414Provider last certified this registry record 25 Oct 2023.
Industry payments
28 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year202513 payments$12,079openpaymentsdata.cms.gov ↗
- Legend Biotech USA Inc.Program year20256 payments
- Karyopharm Therapeutics Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
39.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor39.3%Acyclovir100%Part D≥76 patientsMetabolism & gastrointestinal
20%Proton pump inhibitor14.2%Pantoprazole Sodium86%Omeprazole14%Part D<11 patientsSerotonin-3 Receptor Antagonist3.9%Ondansetron Hcl50%Ondansetron Odt50%Part D<11 patients+ 1 more class in this area
Sensory organs
9.8%Corticosteroid9.8%Dexamethasone100%Part D≥23 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine
2025 - Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology
2025 - Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma
Biology of Blood and Marrow Transplantation
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Tait Shanafelt, MD
Palo Alto University
Robert Bast, MD
The University of Texas MD Anderson Cancer Center
Thomas Witzig, MD
Mayo Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”